Literature DB >> 1510189

Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases.

F Berthold1, R Trechow, S Utsch, J Zieschang.   

Abstract

The purpose of our study was to investigate the interrelationship of known and possible new risk factors in patients with metastatic neuroblastoma and to define groups at risk. The possible influence of 37 variables on event-free survival (EFS) was analyzed univariately in 308 consecutive patients using the Kaplan-Meier estimate. Fifteen factors were identified (p less than 0.05, logrank greater than 3.84) of whom eight showed a nonrandom correlation to several others (chi 2-test, p less than 0.05). Seven noncorrelated factors [lactate dehydrogenase (LDH) level, resectability of the primary tumor, histologic grade, leukopenia, presence of symptoms, general condition, and age at diagnosis] were included in the multivariate analysis of 182 patients according to the Cox model. The variables LDH (p = 0.0007), resectability (p = 0.0063), histologic grade (p = 0.0055), and leukopenia (p = 0.0470) were identified multivariately as prognostic factors for EFS. These results permitted the classification of patients into three prognostic groups. The 6 year event-free survival for group IV-A (LDH normal) was 0.37 +/- 0.12, for group IV-B (LDH abnormal, additional risk factors favorable) 0.18 +/- 0.10, and for group IV-C (LDH abnormal, 1-3 additional risk factors unfavorable) was 0.08 +/- 0.03. We conclude that the proposed clinicopathological classification may prove to be a reliable and easily applicable tool for estimating the outcome of metastatic neuroblastoma in children.

Entities:  

Mesh:

Year:  1992        PMID: 1510189     DOI: 10.1097/00043426-199208000-00005

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  6 in total

1.  Disseminated neuroblastomas under 1 year of age: cell biology and prognosis.

Authors:  F Lampert; H Christiansen; F Berner; H J Terpe; F Berthold
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Biochemical parameters in neuroblastoma.

Authors:  S T Bolkar; M S Ghadge; A S Raste
Journal:  Indian J Clin Biochem       Date:  2008-10-01

3.  Intensive chemotherapy in children with stage IV neuroblastoma.

Authors:  P Kusumakumari; T V Ajithkumar; S Hariharan; R R Varma; V G Chellam; R Nair; M K Nair
Journal:  Indian J Pediatr       Date:  1999 Nov-Dec       Impact factor: 1.967

4.  Prognostic factors including neoadjuvant chemotherapy in Mexican children with neuroblastoma.

Authors:  Alberto Olaya-Vargas; Roberto Rivera-Luna; Rocío Cárdenas-Cardós; Araceli Castellanos Toledo; Oscar Alberto Pérez González; Julieta Robles Castro; Carlos Calderón Elvir
Journal:  Clin Transl Oncol       Date:  2005 Jan-Feb       Impact factor: 3.405

5.  Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.

Authors:  Frank Berthold; Claudia Spix; Peter Kaatsch; Fritz Lampert
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

6.  Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.

Authors:  Akiko Ioka; Masami Inoue; Akihiro Yoneda; Tetsuro Nakamura; Junichi Hara; Yoshiko Hashii; Naoki Sakata; Kazumi Yamato; Hideaki Tsukuma; Keisei Kawa
Journal:  J Epidemiol       Date:  2015-11-07       Impact factor: 3.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.